A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
PHASE2Active, not recruitingINTERVENTIONAL
Enrollment
57
Participants
Timeline
Start Date
November 30, 2014
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
Conditions
Biliary Tract CarcinomaGallbladder Carcinoma
Interventions
DRUG
Selumetinib
DRUG
Cisplatin
DRUG
Gemcitabine
Trial Locations (1)
M5G 2M9
Princess Margaret Cancer Centre, Toronto
All Listed Sponsors
lead
University Health Network, Toronto
OTHER
NCT02151084 - A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | Biotech Hunter | Biotech Hunter